<DOC>
	<DOCNO>NCT00008450</DOCNO>
	<brief_summary>This pilot clinical trial study total-body irradiation follow cyclosporine mycophenolate mofetil treat patient severe combine immunodeficiency ( SCID ) undergo donor bone marrow transplant . Giving total-body irradiation ( TBI ) donor bone marrow transplant use stem cell closely match patient 's stem cell , help stop growth abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may mix patient 's immune cell help destroy remain abnormal cell . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Total-Body Irradiation Followed By Cyclosporine Mycophenolate Mofetil Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To safely establish partial lymphoid chimerism ( 1-95 % donor cluster differentiation [ CD ] 3+ cell ) use non-lethal conditioning regimen patient severe combined immunodeficiency syndrome . II . To define kinetics immune reconstitution follow non-lethal condition regimen patient immunodeficiency disease . OUTLINE : Patients receive cyclosporine orally ( PO ) intravenously ( IV ) day -3 100 follow taper day 180 mycophenolate mofetil PO IV day 0-40 taper day 96 absence unacceptable toxicity . Unrelated donor recipient also undergo TBI day 0 . Patients undergo bone marrow transplant day 0 . After completion study treatment , patient follow 6 month yearly 5 year .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients severe combined immunodeficiency syndrome : SCID presence B lymphocytes Xlinked SCID ( presence B lymphocytes ) Autosomal recessive SCID Patients severe combine immunodeficiency syndrome : SCID absence T B lymphocytes Patients severe combined immunodeficiency syndrome : Purine metabolite deficiency , deficiency purine metabolite Adenosine deaminase ( ADA ) deficiency Purine nucleoside phosphorylase ( PNP ) deficiency DONOR : Related donor human leukocyte antigen ( HLA ) genotypically identical least one haplotype may genotypically phenotypically identical serological typing HLAA , B , C , allele level DRB1 DQB1 ; relate donor sibling must match HLAA , B , C ( high resolution available time donor selection ) DRB1 DQB1 deoxyribonucleic acid ( DNA ) typing ; one HLAidentical sibling available , priority give old normal donor DONOR : Unrelated donor prospectively match HLAA , B , C , DRB1 DQB1 DNA type high resolution routinely available time donor selection ; single allele disparity allow HLAA , B , C define high resolution type Patients viral associate T cell immunodeficiency disorder , human immunodeficiency virus ( HIV ) Patients disease organ dysfunction would limit survival less 30 day DONOR : Identical twin DONOR : Pregnancy DONOR : HIV seropositive DONOR : A positive antidonor cytotoxic cross match absolute donor exclusion DONOR : Patient donor pair homozygous mismatch allele graft rejection vector consider twoHLA allele mismatch , i.e. , patient A*0201 , type mismatch allow DONOR : &lt; 6 month old , &gt; 75 year old</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>